A Single Arm Phase II Trial of the Intraoperative Intravesical Instillation of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract
To determine the one year bladder tumor recurrence rate in patients with urothelial carcinoma of the upper urinary tract following intraoperative administration of mitomycin C
Evaluate the time to bladder tumor recurrence in patients with urothelial carcinoma of the upper respiratory tract following intraoperative administration of mitomycin C
- Both males and females ≥ eighteen years of age
- Histologically proven diagnosis of urothelial carcinoma of the renal pelvis and/or ureter. No other histology is allowed.
- The TNM stage of the subject's disease (using the American Joint Committee on Cancer [AJCC] Cancer Staging Manual, 8th Edition) must be Tis, Ta, T1, T2, or T3, N0, M0. Subjects may have either a high-grade or low-grade tumor.
- ECOG performance status of 0-2
- Written informed consent obtained from the subject or the subject's legal representative and the ability for the subject to comply with all the study-related procedures.
- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy prior to and for at least 3 months after mitomycin C instillation to minimize the risk of pregnancy. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
- Males with female partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) should avoid conceiving children prior to and for 3 months following mitomycin C instillation
- Subjects must have hemoglobin ≥ 9 g/dL and a platelet count ≥ 100,000/μL.
- Active urothelial carcinoma of the bladder within 12 months prior to enrollment
- History of adverse reaction to mitomycin C
- Evidence of regional or metastatic disease.
- History of radical cystectomy
- Planned radical cystectomy at the time of nephroureterectomy
- Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy prior to and for at least 3 months after mitomycin C instillation.
- Females who are pregnant or breastfeeding.
- History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
- Prisoners or subjects who are involuntarily incarcerated.
- Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
- Subjects demonstrating an inability to comply with the study and/or follow-up procedures
Principal InvestigatorPaul L Crispen, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.